DrugPatentWatch Database Preview
Drugs in Development Information for Momelotinib
» See Plans and Pricing
What is the drug development status for Momelotinib?
Momelotinib is an investigational drug.
There have been 14 clinical trials for Momelotinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2013.
The most common disease conditions in clinical trials are Thrombocytosis, Thrombocythemia, Essential, and Primary Myelofibrosis. The leading clinical trial sponsors are Gilead Sciences, Sierra Oncology, Inc., and Fred Hutchinson Cancer Research Center.
There are twenty-seven US patents protecting this investigational drug and three hundred and twelve international patents.
Summary for Momelotinib
| US Patents | 27 |
| International Patents | 312 |
| US Patent Applications | 57 |
| WIPO Patent Applications | 42 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2013-12-01) |
| Vendors | 85 |
Recent Clinical Trials for Momelotinib
| Title | Sponsor | Phase |
|---|---|---|
| A Phase 3 Study Comparing the Activity of Momelotinib in Symptomatic and Anemic Myelofibrosis Patients Versus Danazol | Sierra Oncology, Inc. | Phase 3 |
| Extended Access of Momelotinib in Adults With Myelofibrosis | Gilead Sciences | Phase 2 |
| Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) | Gilead Sciences | Phase 2 |
Clinical Trial Summary for Momelotinib
Top disease conditions for Momelotinib
Top clinical trial sponsors for Momelotinib
US Patents for Momelotinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Momelotinib | Start Trial | Benzimidazole derivatives as bromodomain inhibitors | Gilead Sciences, Inc. (Foster City, CA) | Start Trial |
| Momelotinib | Start Trial | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (Atlanta, GA) | Start Trial |
| Momelotinib | Start Trial | Tank-binding kinase inhibitor compounds | Gilead Sciences, Inc. (Foster City, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Momelotinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Momelotinib | Argentina | 096246 | 2033-05-09 | Start Trial |
| Momelotinib | Australia | 2014262622 | 2033-05-09 | Start Trial |
| Momelotinib | Brazil | 112015028017 | 2033-05-09 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
